EBF3 and retinoblastoma: A recent multiomics study has led to a better understanding of the molecular landscape of retinoblastoma with the identification of 2 subtypes, subtype 1 occurring at an early age with very few mutations and preservation of late cone markers (e.g. ARR3), and subtype 2 occurring later, with a slightly increased mutation burden, aneuploidies, ganglion/neuronal (e.g. EBF3) and stemness genes expression, as well as an increased metastatic risk (with TFF1 as a proposed marker) [11].